Mini Omega 3x Fish Oil Softgels

Description

Mini Omega 3x™ features a patented delivery system for EPA and DHA fish oils has increased absorption by a heavy-hitting 300%. This delivery system allows for significantly lower dosages and smaller capsules. It uses monoglyceride vs. triglyceride fish oil molecules which are, by nature, in a readily absorbable form and bypass the body’s normal fat digestion process in the liver and pancreas.*

LifeSpa’s Mini Omega 3X Fish Oil Softgels deliver EPA and DHA beneficial fish oils at three times the absorption rate to deliver the omega-3s directly into the bloodstream.

Suggested Use: Take one softgel daily, or as directed by your healthcare practitioner.

Consult your healthcare practitioner prior to use. Individuals taking blood thinners or other medication should discuss potential interactions with their healthcare practitioner. Do not use if tamper seal is damaged.

Bottle Contains: 60 capsules

Ingredients: MaxSimil® Fish Oil Concentrate, EPA (eicosapentaenoic acid), DHA (docosahexaenoic acid)

Other Ingredients: Softgel (fish gelatin, vegetable glycerin, and purified water), GRAS enteric coating (ethylcellulose, sodium alginate, purified water, medium-chain triglycerides, oleic acid, vegetable stearic acid, and ammonium hydroxide), and mixed natural tocopherols.

Contains: Fish (anchovy and/or sardine [sources of fish oil], tilapia and/or pangasius [sources of fish gelatin]).

Does Not Contain: Wheat, gluten, corn, yeast, soy protein, dairy products, shellfish, peanuts, tree nuts, egg, ingredients derived from genetically modified organisms (GMOs), artificial colors, artificial sweeteners, or artificial preservatives.

---

Detox Your Brain & Gut With This Surprising Lymph Cleanser

For decades, heart health has been the claim to fame for omega-3 fish oil supplementation, but mounting research is suggesting the effect may extend life as well.

The newest research showed that those who consumed the highest amount of omega-3s from fish oils had a 14% reduction in risk of death from any cause. (1)

This benefit is called “all-cause mortality,” and is the gold standard in measuring the effect of an intervention on lifespan. (1)

This meta-analysis combined 23 independent studies and involved more than one million subjects who were evaluated for fish and fish oil consumption. The results of this massive study suggest that the regular consumption of omega-3 fatty acids, like those found in fish oil (DHA and EPA), reveal impressive changes in lifespan.

While previous studies suggest that increased omega-3 consumption supports healthy brain, mood, and heart function (2,3), the longevity benefits seen may be due to the lymphatic system support that omega-3s provide.

Aging and the Lymphatic System

As we age, our lymphatic duct efficiency is reduced. Here are some of the effects of aging on the lymph system:

1. The accumulation of fat deposits in lymph ducts (4)
2. Increased number of lymph duct irregularities (4)
3. Lymph duct wall thickening and fibrosis (scarring) (4)
4. Decline in lymph wall elasticity (4)
5. Significant decrease in lymph-collecting vessels in the small intestine in those over age 65 (4)

By now, you may have heard about the newly deemed 79^th organ of the body: the mesentery. The mesentery is lymph-concentrated connective tissue that connects our intestines to the wall of our abdomen.

This area of the body may be the body’s most valuable concentration of lymph, source of immunity and driver of longevity. (4,5,6) The mesentery lymph is particularly vulnerable to oxidative stress as we age. (6)

Remember, the lymphatic system plays three integral roles in the body:

1. It delivers triglyceride fats for baseline energy to the body.
2. It is the carrier of the immune system.
3. It is the body’s primary waste removal system.

>>> Learn more about the lymphatic system here

Age-related breakdown of the mesenteric lymph that lines the intestines can alter the delicate balance of the intestinal epithelium (skin) and the health of the microbiome — all three of which are linked to each other. These mesenteric lymph tissues are designed to deliver good fats for energy as well as send bad fats that are too big for the bloodstream to be processed and detoxified. As they break down with age, the body’s ability to remove toxins and deliver energy can become compromised.

Fish Oils Boost Lymphatic Flow

One of the top solutions to care for aging lymphatic channels is to feed the body with high-quality, lymph-moving fats.

In a handful of recent studies, omega-3 fatty acids from fish oil (EPA and DHA) showed significant support for healthy lymphatic function. (7-9)

For example, they were found to support the removal of toxins from the intestinal wall by helping to flush toxins into the lymphatic channels that drain the intestinal tract – A process that may maintain intestinal health and integrity. (7) Lack of intestinal integrity is directly linked to frustrating health concerns like food intolerances and digestive imbalances.

As the body ages, less omega-3 fatty acids are found in the brain. New research suggests that omega-3 fatty acids from fish oil support healthy lymph circulation in the brain, which may help to explain some of the longevity and cognitive benefits gleaned from fish oil supplementation. (10,11)

Get 3x the Benefits Out Of Your Fish Oils

After 5 decades of mass consumption of processed foods and refined/cooked vegetable oils, many Americans have compromised pancreatic and gallbladder function and overall weakened digestive strength. Consequently, many have difficulty breaking down traditional fish oils, requiring them to take massive dosages to achieve clinical results.

A patented delivery system for EPA and DHA fish oils has increased absorption by a heavy-hitting 300%. This delivery system allows for significantly lower dosages and smaller capsules. It uses monoglyceride vs. triglyceride fish oil molecules which are, by nature, in a readily absorbable form and bypass the body’s normal fat digestion process in the liver and pancreas.

LifeSpa’s Mini Omega 3X Fish Oil Softgels deliver EPA and DHA beneficial fish oils at three times the absorption rate to deliver the omega-3s directly into the bloodstream.

>>> Learn more about fish oils here

References:

1. https://www.ncbi.nlm.nih.gov/pubmed/28802305
2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3976923/
3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4153275/
4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3609606/
5. https://www.eurekalert.org/pub_releases/2016-12/uol-isi121616.php
6. https://www.ncbi.nlm.nih.gov/pubmed/22540739
7. http://www.ncbi.nlm.nih.gov/pubmed/22093738
8. http://www.ncbi.nlm.nih.gov/pubmed/26927910
9. http://www.ncbi.nlm.nih.gov/pubmed/10613412
10. https://www.ncbi.nlm.nih.gov/pubmed/?term=omega+glymphatic
11. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4960264/

---

Additional Science

MaxSimil® Patented Lipid Absorption Enhancement Technology (PLATform)

The MaxSimil PLATform is a novel monoglyceride delivery system that enhances absorption of lipid-based and lipid-soluble nutraceutical and food ingredients. This technology has been applied to LifeSpa®’s Mini Omega 3x™ in order to create a unique vehicle by which to deliver EPA and DHA. Due to the fact that monoglyceride oils are intrinsically emulsifiers and are, by nature, in a readily absorbable form (Figure 1), they can bypass the body’s normal fat digestion process. These qualities make Mini Omega 3x™ an excellent method for delivering omega-3 fatty acids, especially to individuals with digestive, pancreatic, or gallbladder challenges. Studies show that MaxSimil fish oils (FO) have three times (300%) greater absorption of EPA and DHA compared to other leading fish oils.*[1-3]

Quality

Mini Omega 3x™ is made using proprietary MaxSimil compositions containing monoglyceride FO with no additional ingredients, carriers, or excipients. Each fish-gelatin softgel is enteric-coated, and every batch of fish oil is IFOS five-star certified to ensure the world’s highest standards for purity, potency, and freshness. The fish oil is non-GMO, certified sustainable from Scandinavia, and antibiotic-free. Additionally, it is eco-friendly because the greater absorption of EPA and DHA ultimately means that fewer grams of fish oil need to be harvested for the same benefit.*

In Vitro and In Vivo Animal Studies

The ability of MaxSimil-enhanced EPA and DHA to positively influence growth inhibition and apoptosis in colorectal, breast, lung, and prostate diseased cell lines was first demonstrated in a series of in vitro studies.[4-6] Researchers subsequently set out to demonstrate efficacy in animal models after oral administration. In three separate animal models, MaxSimil EPA and DHA forms showed superior activity on diseased cell-line growth inhibition and cytokine production when compared to control, corn oil, krill oil, or the parent forms ethyl ester (EE) EPA and ethyl ester (EE) DHA.[4,7,8] These in vivo animal studies proved that orally supplemented MaxSimil EPA and DHA were well-absorbed and bioactive. Researchers postulated that the observed superior effects of MaxSimil EPA and DHA forms were the result of enhanced absorption, and they set out to prove this hypothesis.*

Preclinical Bioavailability Studies

The in vivo pharmacokinetic studies in rodents involved a comparison between MaxSimil DHA FO and its parent EE DHA FO and an analysis of blood concentrations of DHA over time. The doses used were equivalent to human doses of 3 g/day and 30 g/day; the latter was included primarily to investigate toxicity at high doses. Researchers found that MaxSimil DHA FO had a three times (3x) higher peak concentration (6% versus 2%, Figure 2), a 3x higher saturation potential at the high dose (10% versus 3%), and a 3x higher absorption rate (at a 3 g/day equivalent human dose) than its parent DHA FO. No toxicity was observed at either dose level.[1,2] This research demonstrated superior bioavailability and presumably better exposure of cells to DHA.*

Preclinical Bioavailability Studies

The in vivo pharmacokinetic studies in rodents involved a comparison between MaxSimil DHA FO and its parent EE DHA FO and an analysis of blood concentrations of DHA over time. The doses used were equivalent to human doses of 3 g/day and 30 g/day; the latter was included primarily to investigate toxicity at high doses. Researchers found that MaxSimil DHA FO had a three times (3x) higher peak concentration (6% versus 2%, Figure 2), a 3x higher saturation potential at the high dose (10% versus 3%), and a 3x higher absorption rate (at a 3 g/day equivalent human dose) than its parent DHA FO. No toxicity was observed at either dose level.[1,2] This research demonstrated superior bioavailability and presumably better exposure of cells to DHA.*

Clinical Bioavailability Study

A phase 1, double-blind, randomized, crossover, pharmacokinetic study was performed in 20 healthy adults aged between 19 and 71 years who were administered 6 g (containing 1800 mg EPA and 1200 mg DHA) per day of EE FO or MaxSimil FO.[3] Parameters studied were plasma EPA and DHA concentration (as percent of total fatty acids), Cmax, and AUC. Compared to EE EPA+DHA, the results indicated that at peak concentration, MaxSimil EPA and DHA forms were 3x higher, they reached maximum concentration faster, and maintained their plasma levels longer (Figure 3). The finding in the animal study was validated: the MaxSimil FO instantaneous absorption was 3x greater than the EE form. Likewise, the AUC over 24 hours was also more than 3x higher (P<.0001) for MaxSimil EPA and DHA (MaxSimil FO).*

Not only did this study confirm the bioavailability findings in the animal study, but it also demonstrated that after 24 hours, the MaxSimil FO maintained 2-3x higher blood levels of EPA and DHA than the EE FO. This means that, given a daily dose, circulating EPA and DHA levels can be expected to ramp up over time and remain high with steadily increasing exposure of cells to EPA, DHA, and their metabolites. Based on the results of the bioavailability studies, an individual would get more EPA and DHA from MaxSimil FO than from EE FO gram for gram. Furthermore, as shown in the animal studies, one could anticipate enhanced effects. It is noteworthy that all 20 adults who completed the study saw their omega-3 absorption enhanced when taking the MaxSimil enhanced FO.*

Expanding Research

In vitro and animal studies have demonstrated the positive effects of MaxSimil FO on airway immune response (e.g., IgE, leukocytes); the expression of COX-2, NF-kB, cytokines (e.g., IL-6, IL-8), MUC5AC, and mucin; and Ca(2+) hypersensitivity in lung tissues.[8-11] In other research, rats subjected to eight weeks of a high-fat, high-carbohydrate diet were either not supplemented or provided 3 g/day of MaxSimil DHA. Compared to the data from the non-supplemented group, the data from the MaxSimil DHA supplemented group clearly showed a positive impact on cardiovascular health parameters. Measures included blood pressure, heart rate, serum lipid levels, cytokine production, aortic wall thickness, and a DHA:AA ratio in aortic tissue, which correlated with the production of resolvin D2 and D3 metabolites.*[12]

A Note About Resolvins and Other EPA and DHA Metabolites

Specialized pro-resolving lipid mediators, such as resolvins, protectins, and maresins, are EPA and DHA metabolites naturally produced in vivo through enzymatic conversion of EPA and DHA. These mediators aid the body’s “clean-up” response to the arachidonic acid cascade.[13] Rather than supplying a single molecule or metabolite, which would mirror the pharmaceutical model, Mini Omega 3x™ fish oils provide all the benefits of EPA and DHA as well as the expected and desirable benefits of their metabolites.*

 

References:

1. Unpublished, internal data. Ingenutra.
2. Fortin S, inventor; Centre de Recherche sur les Biotechnologies Marines, assignee. Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof. US patent 8,198,324. June 12, 2012.
3. MaxSimil Patented Lipid Absorption Technology Clinical Study Report: MaxSimil® 3020 Omega-3. Sherbrooke (Québec), Canada: Ingenutra; 2015. [Unpublished, internal data]
4. http://www.ncbi.nlm.nih.gov/pubmed/23932824
5. Fortin S, inventor; Centre de Recherche sur les Biotechnologies Marines, assignee. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof. US patent 8,119,690. February 21, 2012.
6. Fortin S, inventor; Centre de Recherche sur les Biotechnologies Marines, assignee. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof. US patent 8,329,747. December 11, 2012.
7. http://www.ncbi.nlm.nih.gov/pubmed/26022389
8. http://www.ncbi.nlm.nih.gov/pubmed/21057106
9. http://www.ncbi.nlm.nih.gov/pubmed/23957343
10. http://www.ncbi.nlm.nih.gov/pubmed/25781052
11. Morin C, Fortin S, Rousseau É. New omega-3 derivatives reduce airway inflammation and prevent rho-kinase activation in an allergic model of asthma. J Aller Ther. 2012;3(S1):003. doi:10.4172/2155-6121.S1-003.
12. http://www.ncbi.nlm.nih.gov/pubmed/25910811
13. http://www.ncbi.nlm.nih.gov/pubmed/22326554
14. http://www.ncbi.nlm.nih.gov/pubmed/23432189
15. http://www.ncbi.nlm.nih.gov/pubmed/27114468
16. http://www.ncbi.nlm.nih.gov/pubmed/25115436
17. http://www.ncbi.nlm.nih.gov/pubmed/17375118
18. http://www.ncbi.nlm.nih.gov/pubmed/17684203
19. http://www.ncbi.nlm.nih.gov/pubmed/17617938
20. http://www.ncbi.nlm.nih.gov/pubmed/16488419
21. http://www.ncbi.nlm.nih.gov/pubmed/24886626
22. http://www.ncbi.nlm.nih.gov/pubmed/22440854
23. http://www.ncbi.nlm.nih.gov/pubmed/20209466

keyword: omega3